Aurobindo Pharma to acquire under development product, related assets from Advent for $12.5mn

The acquisition is for a cash consideration of USD 12.5 million, it added. The indicative time period for completion of the acquisition is January 2019, Aurobindo Pharma said.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2DE0ZSO
via IFTTT